The strategy of piking a target : What is aktually most effective?
(2018) In Clinical Cancer Research 24(9). p.2029-2031- Abstract
Breast and gynecologic cancers harboring PIK3CA mutations showed no significant responses to AZD5363, a pan-AKT catalytic inhibitor, in contrast with previous in vitro data showing activity of the drug in this subset of cancers. These results raise the question of how to select the most accurate predictive biomarkers of response.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/55abbf09-9561-4560-857f-1642bb585414
- author
- Costa, Carlotta and Bosch, Ana LU
- organization
- publishing date
- 2018-05-01
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Clinical Cancer Research
- volume
- 24
- issue
- 9
- pages
- 3 pages
- publisher
- American Association for Cancer Research
- external identifiers
-
- pmid:29374052
- scopus:85047831421
- ISSN
- 1078-0432
- DOI
- 10.1158/1078-0432.CCR-17-3440
- language
- English
- LU publication?
- yes
- id
- 55abbf09-9561-4560-857f-1642bb585414
- date added to LUP
- 2018-06-14 13:32:22
- date last changed
- 2024-04-29 09:59:02
@article{55abbf09-9561-4560-857f-1642bb585414,
abstract = {{<p>Breast and gynecologic cancers harboring PIK3CA mutations showed no significant responses to AZD5363, a pan-AKT catalytic inhibitor, in contrast with previous in vitro data showing activity of the drug in this subset of cancers. These results raise the question of how to select the most accurate predictive biomarkers of response.</p>}},
author = {{Costa, Carlotta and Bosch, Ana}},
issn = {{1078-0432}},
language = {{eng}},
month = {{05}},
number = {{9}},
pages = {{2029--2031}},
publisher = {{American Association for Cancer Research}},
series = {{Clinical Cancer Research}},
title = {{The strategy of piking a target : What is aktually most effective?}},
url = {{http://dx.doi.org/10.1158/1078-0432.CCR-17-3440}},
doi = {{10.1158/1078-0432.CCR-17-3440}},
volume = {{24}},
year = {{2018}},
}